ZIMMER BIOMET HOLDINGS, INC.
ZBHNYSE · SIC 3842
$91.12
↓ -2.8%Jul 17 close · end-of-day
Price
1Y↓ -2.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$17.8B
Enterprise Value
$24.9B
P/E
23.6
P/S
2.1
P/B
1.4
EV/EBITDA
10.9
PEG
0.5
FCF Yield
8.2%
Dividend Yield
1.1%
Revenue (TTM)
$8.4B
Net Income (TTM)
$761.2M
Free Cash Flow (TTM)
$1.5B
Gross Margin
—
Operating Margin
14.0%
Net Margin
9.0%
ROE
6.0%
ROIC
5.0%
Debt / Equity
0.6
Net Cash
-$7.0B
Return 1Y
-3.0%
Company profile
Zimmer Biomet Holdings, Inc. operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products.
- CEO
- Bryan C. Hanson
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 18,000
- Headquarters
- Indiana
- Website
- zimmerbiomet.com
Earnings
Next earnings · estimated2026-07-28
ZBH Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.1B↑ +9.3%
Diluted EPS$1.22↑ +34.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $6.1B | $6.8B | $6.9B | $7.4B | $7.7B | $8.2B |
| Gross profit | — | — | — | — | — | — |
| Operating income | $83.1M | $860.3M | $696.3M | $1.3B | $1.3B | $1.1B |
| Net income | -$138.9M | $401.6M | $231.4M | $1.0B | $903.8M | $705.1M |
| Diluted EPS | -$0.67 | $1.91 | $1.10 | $4.88 | $4.43 | $3.55 |
| Operating cash flow | $1.2B | $1.5B | — | $1.6B | $1.5B | $1.7B |
| Free cash flow | $1.1B | $1.4B | — | $1.3B | $1.3B | $1.5B |
| Gross margin | — | — | — | — | — | — |
| Operating margin | 1.4% | 12.6% | 10.0% | 17.3% | 16.7% | 13.3% |
| Net margin | -2.3% | 5.9% | 3.3% | 13.8% | 11.8% | 8.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.9B | $1.8B | $2.0B | $1.9B | $2.1B | $2.0B | $2.2B | $2.1B |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $351.3M | $279.5M | $389.0M | $292.3M | $300.0M | $351.3M | $154.5M | $373.2M |
| Net income | $242.8M | $249.1M | $239.5M | $182.0M | $152.8M | $230.9M | $139.4M | $238.1M |
| Diluted EPS | $1.18 | $1.23 | $1.18 | $0.91 | $0.77 | $1.16 | $0.71 | $1.22 |
| Operating cash flow | $369.4M | $395.7M | $506.3M | $382.8M | $378.2M | $418.7M | $517.4M | $359.4M |
| Free cash flow | $316.7M | $351.2M | $454.8M | $338.2M | $328.1M | $363.7M | $442.6M | $323.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 18.1% | 15.3% | 19.2% | 15.3% | 14.4% | 17.6% | 6.9% | 17.9% |
| Net margin | 12.5% | 13.7% | 11.8% | 9.5% | 7.4% | 11.5% | 6.2% | 11.4% |
Company news
Jul 20, 2026
Jul 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-29 | Yi Sang· Group President, Asia Pacific | Sale | 4,200 | $82.64 | $347,088.00 | filing |
| 2026-05-29 | Yi Sang· Group President, Asia Pacific | Sale | 800 | $82.66 | $66,128.00 | filing |
Latest 2 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.